These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 30360669)

  • 21. A case series of aripiprazole augmentation of selective serotonin reuptake inhibitors in treatment-refractory obsessive compulsive disorder.
    Matsunaga H; Hayashida K; Maebayashi K; Mito H; Kiriike N
    Int J Psychiatry Clin Pract; 2011 Nov; 15(4):263-9. PubMed ID: 22121999
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder.
    Matsunaga H; Nagata T; Hayashida K; Ohya K; Kiriike N; Stein DJ
    J Clin Psychiatry; 2009 Jun; 70(6):863-8. PubMed ID: 19422759
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serotonin reuptake inhibitor-cognitive behavioural therapy-second generation antipsychotic combination for severe treatment-resistant obsessive-compulsive disorder. A prospective observational study.
    Tundo A; Salvati L; Cieri L; Balestrini V; Di Spigno D; Orazi F; Iommi M; Necci R
    Int J Psychiatry Clin Pract; 2022 Nov; 26(4):395-400. PubMed ID: 35323098
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 10-week open-label study.
    Ak M; Bulut SD; Bozkurt A; Ozsahin A
    Adv Ther; 2011 Apr; 28(4):341-8. PubMed ID: 21437763
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Comparative Study of Aripiprazole, Olanzapine, and L-Methylfolate Augmentation in Treatment Resistant Obsessive-Compulsive Disorder.
    Dar SA; Wani RA; Haq I
    Psychiatr Q; 2021 Dec; 92(4):1413-1424. PubMed ID: 33830427
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risperidone augmentation of specific serotonin reuptake inhibitors in the treatment of refractory obsessive-compulsive disorder: report of two cases.
    Sun TF; Lin PY; Wu CK
    Chang Gung Med J; 2001 Sep; 24(9):587-92. PubMed ID: 11725630
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical features of patients with obsessive-compulsive disorder showing different pharmacological responses].
    Sumitani S; Ueno S; Ishimoto Y; Taniguchi T; Tomotake M; Motoki I; Yamauchi K; Ohmori T
    Seishin Shinkeigaku Zasshi; 2006; 108(12):1282-92. PubMed ID: 17334085
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder.
    McDougle CJ; Epperson CN; Pelton GH; Wasylink S; Price LH
    Arch Gen Psychiatry; 2000 Aug; 57(8):794-801. PubMed ID: 10920469
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Successful Treatment Response with Aripiprazole Augmentation of SSRIs in Refractory Obsessive-Compulsive Disorder in Childhood.
    Akyol Ardic U; Ercan ES; Kutlu A; Yuce D; Ipci M; Inci SB
    Child Psychiatry Hum Dev; 2017 Oct; 48(5):699-704. PubMed ID: 27812841
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder.
    Saxena S; Wang D; Bystritsky A; Baxter LR
    J Clin Psychiatry; 1996 Jul; 57(7):303-6. PubMed ID: 8666572
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis.
    Maher AR; Maglione M; Bagley S; Suttorp M; Hu JH; Ewing B; Wang Z; Timmer M; Sultzer D; Shekelle PG
    JAMA; 2011 Sep; 306(12):1359-69. PubMed ID: 21954480
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Augmentation with cognitive behavioural therapy has superior efficacy to augmentation with risperidone for treating adults with treatment-resistant OCD.
    O'Neill J
    Evid Based Ment Health; 2014 May; 17(2):58-9. PubMed ID: 24713316
    [No Abstract]   [Full Text] [Related]  

  • 33. Effectiveness of Risperidone Augmentation in Obsessive-Compulsive Disorder: Experience From a Specialty Clinic in India.
    Hegde A; Kalyani BG; Arumugham SS; Narayanaswamy JC; Math SB; Reddy YC
    J Clin Psychopharmacol; 2016 Aug; 36(4):381-4. PubMed ID: 27219093
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aripiprazole augmentation in treating comorbid bipolar disorder and obsessive-compulsive disorder: A systematic review.
    Amerio A; Odone A; Ghaemi SN
    J Affect Disord; 2019 Apr; 249():15-19. PubMed ID: 30743017
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Do antipsychotics ameliorate or exacerbate Obsessive Compulsive Disorder symptoms? A systematic review.
    Sareen J; Kirshner A; Lander M; Kjernisted KD; Eleff MK; Reiss JP
    J Affect Disord; 2004 Oct; 82(2):167-74. PubMed ID: 15488245
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The use of antipsychotics in obsessive compulsive disorder.
    Conti D; Girone N; Boscacci M; Casati L; Cassina N; Cerolini L; Giacovelli L; Viganò C; Conde MM; Cremaschi L; Dell'Osso BM
    Hum Psychopharmacol; 2024 May; 39(3):e2893. PubMed ID: 38340275
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quetiapine augmentation in obsessive-compulsive disorder resistant to serotonin reuptake inhibitors: an open-label study.
    Bogan AM; Koran LM; Chuong HW; Vapnik T; Bystritsky A
    J Clin Psychiatry; 2005 Jan; 66(1):73-9. PubMed ID: 15669891
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Augmentation agents to serotonin reuptake inhibitors for treatment-resistant obsessive-compulsive disorder: A network meta-analysis.
    Zhou DD; Zhou XX; Li Y; Zhang KF; Lv Z; Chen XR; Wan LY; Wang W; Wang GM; Li DQ; Ai M; Kuang L
    Prog Neuropsychopharmacol Biol Psychiatry; 2019 Mar; 90():277-287. PubMed ID: 30576763
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder.
    Mohr N; Vythilingum B; Emsley RA; Stein DJ
    Int Clin Psychopharmacol; 2002 Jan; 17(1):37-40. PubMed ID: 11800505
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series.
    Weiss EL; Potenza MN; McDougle CJ; Epperson CN
    J Clin Psychiatry; 1999 Aug; 60(8):524-7. PubMed ID: 10485634
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.